Nucala denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for nucala are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits Nucala Quantities — and Why You Can Appeal

Nucala (mepolizumab) is a biologic therapy used in severe eosinophilic asthma and certain other eosinophil-driven conditions. Cigna's quantity-limit denials for Nucala typically reflect the insurer's attempt to match dispensing frequency and supply to the dosing schedule authorized in its coverage policy. If your prescription was written for a quantity or supply that exceeds what Cigna's policy allows per fill or per authorization period, the claim will be automatically denied at the pharmacy or by the medical benefit — regardless of whether your physician's order is entirely consistent with the FDA-approved prescribing information.

### Why This Denial Is Appealable

Quantity-limit denials are among the most routinely overturned on appeal because the limit Cigna sets may not align with the FDA-approved dosing schedule for your specific indication, or your prescriber may have documented a clinical reason for the quantity ordered. Cigna is required by federal and state law to give you a full-and-fair review. Under ERISA §503 (for employer-sponsored plans) and ACA §2719 (for most commercial plans), you have the right to an internal appeal followed by an independent external review if the internal appeal is denied.

### Federal Appeal Framework

• Internal appeal: You generally have 180 days from the denial notice to file. Cigna must decide urgent appeals within 72 hours and standard appeals within 30–60 days depending on plan type.
• External review: If the internal appeal is denied, you may request an independent external review. The external-review window is typically up to four months from the final internal denial. An accredited Independent Review Organization (IRO) — not Cigna — makes the binding decision.
• Expedited option: If a standard timeline would seriously jeopardize your health, request expedited review in writing; decisions are typically required within 72 hours.

### Documentation to Gather

1. Diagnosis confirmation — chart notes, pulmonology or specialist records confirming your diagnosis and its severity. 2. Eosinophil laboratory history — dated lab results your prescriber used to establish eligibility, with clinical interpretation in the chart. 3. Prior treatment history — names, dates, duration, and documented outcomes of all therapies tried before Nucala was selected. 4. Prescriber medical-necessity letter — a letter from your physician explaining why the ordered quantity matches the FDA-approved prescribing label for your indication and why a reduced quantity would be clinically inadequate. 5. FDA label extract — pull the current Nucala prescribing information from the FDA website and highlight the dosing schedule for your approved indication; attach it to the appeal.

### Criteria-Mapping Structure

For each requirement listed in Cigna's published coverage policy for Nucala, create a two-column response:

| Cigna Policy Requirement | Your Chart Evidence | |---|---| | Approved indication confirmed | [Specialist diagnosis note, date] | | Dosing matches labeling | [Prescriber letter citing FDA label section] | | Quantity per fill within policy | [Prescriber justification if quantity differs] |

Attach the FDA-approved prescribing label for Nucala alongside your appeal letter so the reviewer can confirm your prescriber's order is within labeled parameters. Request Cigna's complete coverage policy by name and version number, and address every criterion in it explicitly.